

# Nicola S Meagher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1980650/publications.pdf>

Version: 2024-02-01

24  
papers

660  
citations

623734

14  
h-index

610901

24  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients. American Journal of Transplantation, 2013, 13, 174-183.	4.7	81
2	De novo Cancer-Related Death in Australian Liver and Cardiothoracic Transplant Recipients. American Journal of Transplantation, 2013, 13, 1296-1304.	4.7	69
3	Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. International Journal of Cancer, 2014, 135, 2146-2156.	5.1	62
4	Role of radiotherapy in early glottic carcinoma. Head and Neck, 2010, 32, 850-859.	2.0	54
5	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
6	Survival After Cutaneous Melanoma in Kidney Transplant Recipients: A Population-Based Matched Cohort Study. American Journal of Transplantation, 2014, 14, 1368-1375.	4.7	42
7	Latitude gradients for lymphoid neoplasm subtypes in Australia support an association with ultraviolet radiation exposure. International Journal of Cancer, 2013, 133, 944-951.	5.1	39
8	The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study. BMJ Open, 2012, 2, e001755.	1.9	32
9	Recurrent Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 469-473.	1.3	26
10	High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. Journal of the American Academy of Dermatology, 2016, 74, 1144-1152.e6.	1.2	23
11	Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia. British Journal of Haematology, 2016, 174, 550-562.	2.5	22
12	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	5.5	21
13	Retained role of surgery for olfactory neuroblastoma. Head and Neck, 2011, 33, 1486-1492.	2.0	16
14	The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study. Drug and Alcohol Dependence, 2015, 152, 264-271.	3.2	15
15	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 <sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
16	An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry data. Cancer Epidemiology, 2014, 38, 460-464.	1.9	14
17	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Gynecologic Oncology, 2018, 150, 527-533.	1.4	14
18	Medulloblastoma: Progress over time. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 227-234.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Governance approval for multisite, non-interventional research: what can Harmonisation of Multi-Centre Ethical Review learn from the New South Wales experience?. Internal Medicine Journal, 2012, 42, 127-131.	0.8	11
20	Examining the quality of name code record linkage: what is the impact on death and cancer risk estimates? A validation study. Australian and New Zealand Journal of Public Health, 2015, 39, 141-147.	1.8	9
21	Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability. Biomarker Insights, 2021, 16, 117727192110057.	2.5	9
22	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	2.8	8
23	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. British Journal of Cancer, 2021, 125, 265-276.	6.4	7
24	Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006. Clinical Transplantation, 2015, 29, 978-990.	1.6	6